Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-2-transfected CIK cells (Humboldt University)
- Development stage
- Unknown
- Lead developer
- Humboldt-Universität zu Berlin
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
IL-2-transfected CIK cells are an autologous adoptive cell therapy developed by researchers at the Humboldt University of Berlin. This approach involves harvesting a patient's peripheral blood mononuclear cells and expanding them ex vivo into cytokine-induced killer (CIK) cells—a heterogeneous population of immune effectors with T-cell and NK-cell properties. These cells are then genetically modified via electroporation with a plasmid containing the interleukin-2 (IL-2) gene. The resulting cells produce IL-2 (ranging from 330-1800 pg/10^6 cells/24h), which acts in an autocrine and paracrine manner to enhance their proliferation and tumor-specific cytotoxic activity. Administered intravenously, this therapy has been investigated in Phase I trials for metastatic renal cell carcinoma, metastatic colorectal cancer, and lymphoma, showing a favorable safety profile and potential clinical activity, including a complete response in a lymphoma patient.
- Other names
- IL-2-transfected cytokine-induced killer cellsIL2-transfected cytokine-induced killer cellsIL 2-transfected cytokine-induced killer cellsAutologous IL-2-transfected CIK cellsIL-2-transfected CIK cellsIL2-transfected CIK cellsIL 2-transfected CIK cells
02
Targets
CD226 (DNAX accessory molecule 1)IL-2R (Interleukin-2/interleukin-15 receptor complex)LFA-1 (Integrin αLβ2)NKG2DL (NKG2D ligand family)NKG2D (Natural killer group 2 member D receptor)
Beyond the preview
Go deeper on IL-2-transfected CIK cells (Humboldt University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-2-transfected CIK cells (Humboldt University).